From Wikipedia, the free encyclopedia
DS-1
Identifiers
  • 4-chloro-N-(6,8-dibromo-2-thiophen-2-ylimidazo[1,2-a]pyridin-3-yl)benzamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
CompTox Dashboard ( EPA)
ECHA InfoCard 100.209.966 Edit this at Wikidata
Chemical and physical data
FormulaC18H10Br2ClN3OS
Molar mass511.62 g·mol−1
3D model ( JSmol)
  • s4cccc4-c2nc1c(Br)cc(Br)cn1c2NC(=O)c(cc3)ccc3Cl
   (verify)

DS-1 is a drug from the imidazopyridine family, which is the first drug developed that acts as a GABAA receptor positive allosteric modulator (PAM) selective for the α4 β3 δ subtype, which is not targeted by other GABAA receptor PAMs such as the benzodiazepines or other nonbenzodiazepine drugs. Novel selective drugs such as DS-1 are useful in the study of this receptor subtype. [1] [2] [3]

See also

References

  1. ^ Wafford KA, van Niel MB, Ma QP, Horridge E, Herd MB, Peden DR, et al. (January 2009). "Novel compounds selectively enhance delta subunit containing GABA A receptors and increase tonic currents in thalamus". Neuropharmacology. 56 (1): 182–189. doi: 10.1016/j.neuropharm.2008.08.004. PMID  18762200. S2CID  207224202.
  2. ^ Yakoub K, Jung S, Sattler C, Damerow H, Weber J, Kretzschmann A, et al. (March 2018). "Structure-Function Evaluation of Imidazopyridine Derivatives Selective for δ-Subunit-Containing γ-Aminobutyric Acid Type A (GABAA) Receptors". Journal of Medicinal Chemistry. 61 (5): 1951–1968. doi: 10.1021/acs.jmedchem.7b01484. PMID  29451785.
  3. ^ Solomon VR, Tallapragada VJ, Chebib M, Johnston GA, Hanrahan JR (June 2019). "GABA allosteric modulators: An overview of recent developments in non-benzodiazepine modulators". European Journal of Medicinal Chemistry. 171: 434–461. doi: 10.1016/j.ejmech.2019.03.043. PMID  30928713. S2CID  89619321.